전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved261 programs
ADCLimited DatastaleThe Netherlands Cancer InstitutePhase 2

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

Non-Small Cell Lung Carcinoma; Advanced Non-Small Cell Squamous Lung Cancer · EGFR

#EGFR#ADC#Phase2#antibody-drug-conjugate#Non-SmallCellLungCarcinoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab (Keytruda, 89Zr-Pembrolizumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Merck
Trials 1Status Active
AntibodyLimited DatastaleMaisonneuve-Rosemont HospitalPhase 2

Zevalin (90Y ibritumomab tiuxetan, 90Y ibritumomab tiuxetan (Zevalin))

Non-Hodgkins Lymphoma · Non-Hodgkins Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#monoclonal-antibody#Maisonneuve-Rosemont
Trials 1Status Active
CGTLimited DatastaleBeijing Immunochina Medical Sci…Phase 2

AMT-116 CAR-T cells (AMT-116 CAR-T cells)

Melanoma; Non-small Cell Lung Cancer · Melanoma

#Melanoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleBeijing Immunochina Medical Sci…Phase 2

AMT-253 CAR-T cells (AMT-253 CAR-T cells)

Melanoma; Non-small Cell Lung Cancer · Melanoma

#Melanoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

Active bevacizumab and Active dexamethasone (Active bevacizumab and Active dexamethasone)

Non-Ischemic Central Retinal Vein Occlusion · Non-Ischemic Central Retinal Vein Occlus

#Non-IschemicCentralRetinalVeinOc#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleThe First Affiliated Hospital o…Phase 2

Adebrelimab Combined with Bevacizumab and Docetaxel (Adebrelimab Combined with Bevacizumab and Docetaxel)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#The
Trials 1Status Active
CGTLimited DatastaleBaylor College of MedicinePhase 1

Allogeneic CD5.CAR/28zeta CAR T cells (Allogeneic CD5.CAR/28zeta CAR T cells)

T-cell Acute Lymphoblastic Lymphoma; T-non-Hodgkin Lymphoma · T-cell Acute Lymphoblastic Lymphoma

#T-cellAcuteLymphoblasticLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleKymab LimitedPhase 2

Alomfilimab (Alomfilimab)

Squamous Cell Carcinoma of Head and Neck; Non-small Cell Lung Cancer · Squamous Cell Carcinoma of Head and Neck

#SquamousCellCarcinomaofHeadandNe#Antibody#Phase2#monoclonal-antibody#Non-smallCellLungCancer+1
Trials 1Status Discontinued
AntibodyLimited DatastaleGlaxoSmithKlinePhase 2

Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody, Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab))

Lymphoma, Non-Hodgkin · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#monoclonal-antibody#Lymphoma+2
Trials 1Status Active
AntibodyLimited DatastaleGustave Roussy, Cancer Campus, …Phase 2

atezolizumab (Tecentriq, Anti-PD-L1 antibody atezolizumab)

Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma ) · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#PatientsWithMetastaticTumoursCol+3
Trials 1Status Active
CGTLimited DatastaleHenan Cancer HospitalPhase 2

Anti-Trop2 CAR-NK cell (Anti-Trop2 CAR-NK cell)

Non-Small Cell Lung Cancer NSCLC · TROP2

#TROP2#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleRochePhase 1

atezolizumab (Tecentriq, Atezolizumab and Interleukin-12 Gene Therapy)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
CGTLimited DatastaleMayo ClinicPhase 1

Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563 (Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563)

Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleMayo ClinicPhase 1

Autologous BAFFR-targeting CAR T Cells (Autologous BAFFR-targeting CAR T Cells)

B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/CD19 dual-target CAR-T module (Autologous BCMA/CD19 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/CD38 dual-target CAR-T module (Autologous BCMA/CD38 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous BCMA/GPRC5D dual-target CAR-T (Autologous BCMA/GPRC5D dual-target CAR-T)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD20 dual-target CAR-T module (Autologous CD19/CD20 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD22 dual-target CAR-T module (Autologous CD19/CD22 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting

6 / 14 pages

← PreviousNext →